Berry Genomics Co.,Ltd (SHE:000710)

Market Cap	3.75B -23.1%
Revenue (ttm)	922.27M -9.3%
Net Income	-210.11M
EPS	-0.59
Shares Out	353.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,821,100
Average Volume	11,248,510
Open	10.50
Previous Close	10.60
Day's Range	10.50 - 10.68
52-Week Range	9.42 - 17.37
Beta	0.66
RSI	52.85
Earnings Date	Apr 29, 2026

About Berry Genomics Co.,Ltd

Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 1,402
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000710

Financial Performance

In 2025, Berry Genomics Co.,Ltd's revenue was 929.82 million, a decrease of -13.76% compared to the previous year's 1.08 billion. Losses were -196.84 million, 2.29% more than in 2024.